Ocular Therapeutix Stock Performance
| OCUL Stock | USD 7.14 0.20 2.88% |
The company holds a Beta of 0.96, which implies possible diversification benefits within a given portfolio. Ocular Therapeutix returns are very sensitive to returns on the market. As the market goes up or down, Ocular Therapeutix is expected to follow. At this point, Ocular Therapeutix has a negative expected return of -0.49%. Please make sure to check Ocular Therapeutix's maximum drawdown, daily balance of power, as well as the relationship between the Daily Balance Of Power and period momentum indicator , to decide if Ocular Therapeutix performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Ocular Therapeutix has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain quite persistent which may send shares a bit higher in April 2025. The latest mess may also be a sign of long-standing up-swing for the company institutional investors. ...more
Actual Historical Performance (%)
One Day Return 2.88 | Five Day Return 2.15 | Year To Date Return (18.31) | Ten Year Return (79.90) | All Time Return (45.70) |
1 | Ocular Therapeutix to Provide Corporate Update During 43rd Annu | 01/08/2025 |
2 | IMMvention Therapeutix enters collaboration with Novo Nordisk | 01/22/2025 |
3 | Insider Trading | 01/28/2025 |
4 | Investment Analysis and Advice - Stock Traders Daily | 01/30/2025 |
5 | Disposition of 6301 shares by Donald Notman of Ocular Therapeutix at 7.84 subject to Rule 16b-3 | 01/31/2025 |
6 | Ocular Therapeutix Announces Upcoming Presentations at the Angi | 02/03/2025 |
7 | Disposition of 11119 shares by Donald Notman of Ocular Therapeutix at 7.81 subject to Rule 16b-3 | 02/04/2025 |
8 | Acquisition by Nayak Sanjay of 111000 shares of Ocular Therapeutix subject to Rule 16b-3 | 02/11/2025 |
9 | Acquisition by Donald Notman of 344115 shares of Ocular Therapeutix at 7.44 subject to Rule 16b-3 | 02/13/2025 |
10 | Opaleye Management Inc. Increases Stake in Protara Therapeutics Inc. | 02/14/2025 |
11 | Ocular Therapeutix to Report Fourth Quarter and Full Year 2024 Results on March 3, 2025 | 02/24/2025 |
12 | Ocular Therapeutix to Present at Two Investor Conferences in March | 02/25/2025 |
| Begin Period Cash Flow | 104.1 M |
Ocular |
Ocular Therapeutix Relative Risk vs. Return Landscape
If you would invest 977.00 in Ocular Therapeutix on December 1, 2024 and sell it today you would lose (263.00) from holding Ocular Therapeutix or give up 26.92% of portfolio value over 90 days. Ocular Therapeutix is currently does not generate positive expected returns and assumes 2.6201% risk (volatility on return distribution) over the 90 days horizon. In different words, 23% of stocks are less volatile than Ocular, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Ocular Therapeutix Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Ocular Therapeutix's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Ocular Therapeutix, and traders can use it to determine the average amount a Ocular Therapeutix's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1859
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | OCUL |
Estimated Market Risk
| 2.62 actual daily | 23 77% of assets are more volatile |
Expected Return
| -0.49 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.19 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Ocular Therapeutix is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Ocular Therapeutix by adding Ocular Therapeutix to a well-diversified portfolio.
Ocular Therapeutix Fundamentals Growth
Ocular Stock prices reflect investors' perceptions of the future prospects and financial health of Ocular Therapeutix, and Ocular Therapeutix fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Ocular Stock performance.
| Return On Equity | -0.97 | ||||
| Return On Asset | -0.27 | ||||
| Profit Margin | (2.84) % | ||||
| Operating Margin | (2.98) % | ||||
| Current Valuation | 770.44 M | ||||
| Shares Outstanding | 157.22 M | ||||
| Price To Earning | (2.69) X | ||||
| Price To Book | 3.19 X | ||||
| Price To Sales | 18.27 X | ||||
| Revenue | 58.44 M | ||||
| Gross Profit | (47.18 M) | ||||
| EBITDA | (66.42 M) | ||||
| Net Income | (80.74 M) | ||||
| Cash And Equivalents | 134.54 M | ||||
| Cash Per Share | 1.75 X | ||||
| Total Debt | 83.39 M | ||||
| Debt To Equity | 0.90 % | ||||
| Current Ratio | 6.14 X | ||||
| Book Value Per Share | 2.25 X | ||||
| Cash Flow From Operations | (70.23 M) | ||||
| Earnings Per Share | (1.29) X | ||||
| Market Capitalization | 1.12 B | ||||
| Total Asset | 252.06 M | ||||
| Retained Earnings | (697.58 M) | ||||
| Working Capital | 197.34 M | ||||
| Current Asset | 106.98 M | ||||
| Current Liabilities | 5.38 M | ||||
About Ocular Therapeutix Performance
By examining Ocular Therapeutix's fundamental ratios, stakeholders can obtain critical insights into Ocular Therapeutix's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Ocular Therapeutix is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 183.21 | 201.23 | |
| Return On Tangible Assets | (0.29) | (0.30) | |
| Return On Capital Employed | (0.34) | (0.36) | |
| Return On Assets | (0.29) | (0.30) | |
| Return On Equity | (0.80) | (0.76) |
Things to note about Ocular Therapeutix performance evaluation
Checking the ongoing alerts about Ocular Therapeutix for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Ocular Therapeutix help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Ocular Therapeutix generated a negative expected return over the last 90 days | |
| The company reported the previous year's revenue of 58.44 M. Net Loss for the year was (80.74 M) with loss before overhead, payroll, taxes, and interest of (47.18 M). | |
| Ocular Therapeutix currently holds about 134.54 M in cash with (70.23 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.75. | |
| Ocular Therapeutix has a frail financial position based on the latest SEC disclosures | |
| Over 86.0% of the company shares are owned by institutional investors | |
| Latest headline from globenewswire.com: Ocular Therapeutix to Present at Two Investor Conferences in March |
- Analyzing Ocular Therapeutix's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Ocular Therapeutix's stock is overvalued or undervalued compared to its peers.
- Examining Ocular Therapeutix's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Ocular Therapeutix's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Ocular Therapeutix's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Ocular Therapeutix's stock. These opinions can provide insight into Ocular Therapeutix's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Ocular Therapeutix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. For more information on how to buy Ocular Stock please use our How to buy in Ocular Stock guide.You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ocular Therapeutix. If investors know Ocular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ocular Therapeutix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.29) | Revenue Per Share | Quarterly Revenue Growth 0.023 | Return On Assets | Return On Equity |
The market value of Ocular Therapeutix is measured differently than its book value, which is the value of Ocular that is recorded on the company's balance sheet. Investors also form their own opinion of Ocular Therapeutix's value that differs from its market value or its book value, called intrinsic value, which is Ocular Therapeutix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ocular Therapeutix's market value can be influenced by many factors that don't directly affect Ocular Therapeutix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ocular Therapeutix's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ocular Therapeutix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ocular Therapeutix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.